Tags

Type your tag names separated by a space and hit enter

Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment.
J Allergy Clin Immunol. 2008 Nov; 122(5):992-1000.JA

Abstract

BACKGROUND

It is difficult to distinguish the early phase of Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) from other ordinary types of drug-induced skin reactions (ODSRs). Levels of several serum soluble factors, including soluble Fas ligand (sFasL), have been reported to be increased in patients with SJS/TEN; however, the marker to predict the onset of SJS/TEN before the development of skin detachment or mucosal lesions has not been identified.

OBJECTIVE

We sought to determine whether sFasL might be a useful marker in the early stages of SJS/TEN.

METHODS

Sera of 19 patients with SJS and 16 patients with TEN at 1 or multiple time points were obtained from Japanese multiple hospitals. The disease onset (day 1) was defined when erosion/ulceration of the mucocutaneous or ocular lesion first developed. For the investigation of soluble factors, including sFasL, TNF-alpha, IFN-gamma, IL-6, and sCD40 ligand, we used ELISAs and Cytometric Bead Arrays.

RESULTS

Before disease onset (day -4 to approximately -2), 7 samples were available, and we detected the highest concentrations of sFasL in 5 (71.4%) of 7 patients. Increased sFasL levels decreased rapidly within 5 days of disease onset. In all 32 patients with ODSRs and 33 healthy control subjects, no increase of sFasL levels was detected. Other soluble factor concentrations did not show significant difference with those seen in patients with SJS/TEN before disease onset and ODSRs.

CONCLUSION

The sFasL levels of sera in patients with SJS/TEN are significantly increased before development of skin detachment, mucosal lesions, or both.

Authors+Show Affiliations

Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.No affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article
Multicenter Study

Language

eng

PubMed ID

18692887

Citation

Murata, Junko, et al. "Increased Soluble Fas Ligand Levels in Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Preceding Skin Detachment." The Journal of Allergy and Clinical Immunology, vol. 122, no. 5, 2008, pp. 992-1000.
Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J Allergy Clin Immunol. 2008;122(5):992-1000.
Murata, J., Abe, R., & Shimizu, H. (2008). Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. The Journal of Allergy and Clinical Immunology, 122(5), 992-1000. https://doi.org/10.1016/j.jaci.2008.06.013
Murata J, Abe R, Shimizu H. Increased Soluble Fas Ligand Levels in Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Preceding Skin Detachment. J Allergy Clin Immunol. 2008;122(5):992-1000. PubMed PMID: 18692887.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. AU - Murata,Junko, AU - Abe,Riichiro, AU - Shimizu,Hiroshi, Y1 - 2008/08/09/ PY - 2008/03/31/received PY - 2008/06/06/revised PY - 2008/06/12/accepted PY - 2008/8/12/pubmed PY - 2008/12/17/medline PY - 2008/8/12/entrez SP - 992 EP - 1000 JF - The Journal of allergy and clinical immunology JO - J Allergy Clin Immunol VL - 122 IS - 5 N2 - BACKGROUND: It is difficult to distinguish the early phase of Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) from other ordinary types of drug-induced skin reactions (ODSRs). Levels of several serum soluble factors, including soluble Fas ligand (sFasL), have been reported to be increased in patients with SJS/TEN; however, the marker to predict the onset of SJS/TEN before the development of skin detachment or mucosal lesions has not been identified. OBJECTIVE: We sought to determine whether sFasL might be a useful marker in the early stages of SJS/TEN. METHODS: Sera of 19 patients with SJS and 16 patients with TEN at 1 or multiple time points were obtained from Japanese multiple hospitals. The disease onset (day 1) was defined when erosion/ulceration of the mucocutaneous or ocular lesion first developed. For the investigation of soluble factors, including sFasL, TNF-alpha, IFN-gamma, IL-6, and sCD40 ligand, we used ELISAs and Cytometric Bead Arrays. RESULTS: Before disease onset (day -4 to approximately -2), 7 samples were available, and we detected the highest concentrations of sFasL in 5 (71.4%) of 7 patients. Increased sFasL levels decreased rapidly within 5 days of disease onset. In all 32 patients with ODSRs and 33 healthy control subjects, no increase of sFasL levels was detected. Other soluble factor concentrations did not show significant difference with those seen in patients with SJS/TEN before disease onset and ODSRs. CONCLUSION: The sFasL levels of sera in patients with SJS/TEN are significantly increased before development of skin detachment, mucosal lesions, or both. SN - 1097-6825 UR - https://www.unboundmedicine.com/medline/citation/18692887/Increased_soluble_Fas_ligand_levels_in_patients_with_Stevens_Johnson_syndrome_and_toxic_epidermal_necrolysis_preceding_skin_detachment_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0091-6749(08)01135-4 DB - PRIME DP - Unbound Medicine ER -